Larimar Therapeutics, Inc. (LRMR) 10-Year Financial Performance & Capital Metrics

LRMR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.Show more

Revenue $0
EBITDA -$91M -118.5%
Net Income -$81M -118.1%
EPS (Diluted) -1.32 -57.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -63.58% -65.7%
ROIC -66.76% -59.9%
Debt/Equity 0.03 -56.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 39.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-103.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM-67.83%

ROCE

10Y Avg-54.48%

5Y Avg-60.22%

3Y Avg-50%

Latest-69.3%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	70K	212K	188K	261K	78K	155K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-70K	-212K	-188K	-261K	-78K	-155K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-2.03%	0.11%	-0.39%	0.7%	-0.99%	1%	-	-	-
Operating Expenses+	73.74M	56.91M	53.69M	62.46M	23.21M	42.65M	50.47M	36.53M	41.76M	90.89M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	19.13M	17.14M	11.95M	12.93M	2.42M	11.4M	12.07M	12.28M	14.09M	17.61M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	54.62M	39.77M	41.74M	49.53M	20.79M	31.25M	38.4M	24.25M	27.67M	73.28M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	82K	0	0	0	0	0
Operating Income+	-73.81M	-57.12M	-53.88M	-62.72M	-23.21M	-42.8M	-50.47M	-36.53M	-41.76M	-90.89M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.08%	0.23%	0.06%	-0.16%	0.63%	-0.84%	-0.18%	0.28%	-0.14%	-1.18%
EBITDA+	-73.74M	-56.91M	-53.69M	-62.46M	-23.14M	-42.65M	-50.14M	-36.21M	-41.45M	-90.57M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.08%	0.23%	0.06%	-0.16%	0.63%	-0.84%	-0.18%	0.28%	-0.14%	-1.19%
D&A (Non-Cash Add-back)	70K	212K	188K	261K	78K	155K	326K	318K	311K	318K
EBIT	-73.48M	-57.65M	-52.76M	-61.07M	-23.21M	-42.8M	-50.47M	-36.53M	-41.76M	-90.89M
Net Interest Income+	-368K	547K	25K	0	0	0	0	0	0	0
Interest Income	438K	894K	996K	0	0	0	0	0	0	0
Interest Expense	806K	347K	971K	0	0	0	0	0	0	0
Other Income/Expense	-473K	-1.06M	947K	-246K	82K	322K	-171K	1.17M	4.81M	10.29M
Pretax Income+	-74.29M	-58.18M	-52.93M	-62.97M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.6M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-300K	-900K	-1.6M	0	0	0	0	0	0
Effective Tax Rate %	1%	0.99%	0.98%	0.97%	1%	1%	1%	1%	1%	1%
Net Income+	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.33M	-50.64M	-35.35M	-36.95M	-80.6M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.03%	0.22%	0.1%	-0.18%	0.62%	-0.83%	-0.2%	0.3%	-0.05%	-1.18%
Net Income (Continuing)	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-33.32	-25.44	-22.76	-22.85	-2.51	-3.56	-2.93	-1.33	-0.84	-1.32
EPS Growth %	-1.2%	0.24%	0.11%	-0%	0.89%	-0.42%	0.18%	0.55%	0.37%	-0.57%
EPS (Basic)	-33.32	-25.44	-22.76	-22.85	-2.51	-3.56	-2.93	-1.33	-0.84	-1.32
Diluted Shares Outstanding	2.23M	2.27M	2.29M	2.69M	9.21M	11.88M	17.16M	25.76M	43.9M	61.26M
Basic Shares Outstanding	2.23M	2.27M	2.29M	2.69M	9.21M	11.88M	17.16M	25.76M	43.9M	61.26M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	188.11M	130.9M	104.92M	121.33M	4.75M	97.95M	72.2M	120.74M	90.17M	195.3M
Cash & Short-Term Investments	185.08M	129.19M	102.05M	118.07M	1.01M	92.64M	70.1M	118.43M	86.79M	183.45M
Cash Only	35.59M	32.35M	40.78M	49.33M	1.01M	68.15M	70.1M	26.82M	26.75M	33.22M
Short-Term Investments	149.48M	96.84M	61.27M	68.73M	0	24.49M	0	91.6M	60.04M	150.24M
Accounts Receivable	1.32M	347K	946K	1.54M	158K	32K	208K	0	0	1.05M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.71M	1.36M	1.93M	1.73M	448K	251K	279K	238K	709K	10.8M
Total Non-Current Assets+	996K	722K	585K	432K	451K	6.73M	6.46M	5.67M	5.76M	4.92M
Property, Plant & Equipment	902K	661K	528K	375K	361K	4.98M	4.46M	3.69M	3.76M	3.72M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	1.34M	0
Other Non-Current Assets	94K	61K	57K	57K	90K	1.76M	2.01M	1.98M	659K	1.2M
Total Assets+	189.11M	131.62M	105.51M	121.76M	5.2M	104.69M	78.67M	126.41M	95.94M	200.22M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.61%	-0.3%	-0.2%	0.15%	-0.96%	19.13%	-0.25%	0.61%	-0.24%	1.09%
Total Current Liabilities+	16.54M	9.89M	7.29M	13.31M	5.89M	8.99M	8.85M	10.71M	9.51M	24.36M
Accounts Payable	0	0	0	909K	3.54M	2.63M	1.66M	1.69M	1.28M	2.42M
Days Payables Outstanding	-	-	-	1.27K	16.56K	6.2K	-	-	-	-
Short-Term Debt	2.94M	3.59M	0	5.46M	0	0	0	0	0	0
Deferred Revenue (Current)	-1000K	-1000K	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	9.05M	6.3M	4.27M	4.65M	0	0	0	0	0	0
Current Ratio	11.37x	13.23x	14.39x	9.12x	0.81x	10.89x	8.16x	11.28x	9.49x	8.02x
Quick Ratio	11.37x	13.23x	14.39x	9.12x	0.81x	10.89x	8.16x	11.28x	9.49x	8.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.45M	0	20M	15.19M	0	6M	5.41M	4.8M	4.71M	4.06M
Long-Term Debt	3.45M	0	20M	15.19M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	6M	5.41M	4.8M	4.71M	4.06M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	20M	9.89M	27.29M	28.49M	5.89M	14.99M	14.25M	15.5M	14.21M	28.41M
Total Debt+	6.39M	3.59M	20M	20.64M	97K	6.52M	6M	5.41M	5.55M	5.12M
Net Debt	-29.21M	-28.76M	-20.78M	-28.69M	-912K	-61.63M	-64.09M	-21.42M	-21.2M	-28.1M
Debt / Equity	0.04x	0.03x	0.26x	0.22x	-	0.07x	0.09x	0.05x	0.07x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-91.58x	-164.62x	-55.48x	-	-	-	-	-	-	-
Total Equity+	169.11M	121.73M	78.22M	93.27M	-694K	89.69M	64.41M	110.9M	81.72M	171.81M
Equity Growth %	0.62%	-0.28%	-0.36%	0.19%	-1.01%	130.24%	-0.28%	0.72%	-0.26%	1.1%
Book Value per Share	75.85	53.51	34.21	34.73	-0.08	7.55	3.75	4.31	1.86	2.80
Total Shareholders' Equity	169.11M	121.73M	78.22M	93.27M	-694K	89.69M	64.41M	110.9M	81.72M	171.81M
Common Stock	27K	27K	27K	37K	6K	15K	18K	43K	43K	64K
Retained Earnings	-179.67M	-237.55M	-289.58M	-350.94M	-23.13M	-65.61M	-116.25M	-151.6M	-188.55M	-269.16M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-207K	-80K	-58K	-33K	0	1K	0	-31K	81K	148K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-59.55M	-51.98M	-43.78M	-51.49M	-22.7M	-42.2M	-42.1M	-27.57M	-33.46M	-70.76M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.11%	0.13%	0.16%	-0.18%	0.56%	-0.86%	0%	0.35%	-0.21%	-1.11%
Net Income	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.6M
Depreciation & Amortization	70K	212K	188K	261K	78K	155K	326K	318K	311K	318K
Stock-Based Compensation	8.58M	0	0	173K	0	2.16M	5.47M	6.62M	0	8.8M
Deferred Taxes	-8.58M	0	0	-9.63M	0	0	0	0	0	0
Other Non-Cash Items	9.09M	10.64M	9.08M	9.78M	129K	10K	-15K	-820K	5.69M	-5.45M
Working Capital Changes	6.73M	-5.5M	-99K	593K	226K	-2.04M	2.75M	1.67M	-2.51M	6.17M
Change in Receivables	-1.01M	970K	-553K	-666K	1.29M	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	4.91M	4.92M	-448K	432K	2.63M	-3.29M	-974K	26K	-403K	1.14M
Cash from Investing+	-92.12M	51.45M	35.65M	-6.87M	-83K	17.09M	24.17M	-90.96M	33.35M	-85.39M
Capital Expenditures	-595K	-660K	-55K	-108K	-83K	-62K	-333K	-100K	-164K	-515K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-19K	35K	35.7M	-6.76M	0	41.93M	24.5K	-90.86K	0	0
Cash from Financing+	129.16M	-2.71M	16.56M	66.91M	19.39M	93.59M	19.89M	75.26M	30K	161.88M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	18M	0	0	0	77K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-60.15M	-52.63M	-43.84M	-51.59M	-22.78M	-42.26M	-42.44M	-27.67M	-33.62M	-71.28M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.13%	0.12%	0.17%	-0.18%	0.56%	-0.86%	-0%	0.35%	-0.22%	-1.12%
FCF per Share	-26.98	-23.14	-19.18	-19.21	-2.47	-3.56	-2.47	-1.07	-0.77	-1.16
FCF Conversion (FCF/Net Income)	0.80x	0.90x	0.84x	0.84x	0.98x	1.00x	0.83x	0.78x	0.91x	0.88x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-54.31%	-39.8%	-52.04%	-71.57%	-49.97%	-95.12%	-65.72%	-40.33%	-38.36%	-63.58%
Return on Invested Capital (ROIC)	-57.13%	-36.79%	-53.73%	-77.1%	-55.29%	-242.7%	-266.74%	-61.01%	-41.76%	-66.76%
Debt / Equity	0.04x	0.03x	0.26x	0.22x	-	0.07x	0.09x	0.05x	0.07x	0.03x
Interest Coverage	-91.58x	-164.62x	-55.48x	-	-	-	-	-	-	-
FCF Conversion	0.80x	0.90x	0.84x	0.84x	0.98x	1.00x	0.83x	0.78x	0.91x	0.88x

Frequently Asked Questions

Growth & Financials

Larimar Therapeutics, Inc. (LRMR) grew revenue by 0.0% over the past year. Growth has been modest.

Larimar Therapeutics, Inc. (LRMR) reported a net loss of $132.0M for fiscal year 2024.

Dividend & Returns

Larimar Therapeutics, Inc. (LRMR) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.

Larimar Therapeutics, Inc. (LRMR) had negative free cash flow of $96.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Larimar Therapeutics, Inc. (LRMR) 10-Year Financial Performance & Capital Metrics

LRMR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$91M -118.5%
Net Income -$81M -118.1%
EPS (Diluted) -1.32 -57.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -63.58% -65.7%
ROIC -66.76% -59.9%
Debt/Equity 0.03 -56.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 39.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-103.79%

EPS CAGR

10Y-

5Y-

3Y-

TTM-67.83%

ROCE

10Y Avg-54.48%

5Y Avg-60.22%

3Y Avg-50%

Latest-69.3%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	70K	212K	188K	261K	78K	155K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-70K	-212K	-188K	-261K	-78K	-155K	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-2.03%	0.11%	-0.39%	0.7%	-0.99%	1%	-	-	-
Operating Expenses+	73.74M	56.91M	53.69M	62.46M	23.21M	42.65M	50.47M	36.53M	41.76M	90.89M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	19.13M	17.14M	11.95M	12.93M	2.42M	11.4M	12.07M	12.28M	14.09M	17.61M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	54.62M	39.77M	41.74M	49.53M	20.79M	31.25M	38.4M	24.25M	27.67M	73.28M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	82K	0	0	0	0	0
Operating Income+	-73.81M	-57.12M	-53.88M	-62.72M	-23.21M	-42.8M	-50.47M	-36.53M	-41.76M	-90.89M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.08%	0.23%	0.06%	-0.16%	0.63%	-0.84%	-0.18%	0.28%	-0.14%	-1.18%
EBITDA+	-73.74M	-56.91M	-53.69M	-62.46M	-23.14M	-42.65M	-50.14M	-36.21M	-41.45M	-90.57M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.08%	0.23%	0.06%	-0.16%	0.63%	-0.84%	-0.18%	0.28%	-0.14%	-1.19%
D&A (Non-Cash Add-back)	70K	212K	188K	261K	78K	155K	326K	318K	311K	318K
EBIT	-73.48M	-57.65M	-52.76M	-61.07M	-23.21M	-42.8M	-50.47M	-36.53M	-41.76M	-90.89M
Net Interest Income+	-368K	547K	25K	0	0	0	0	0	0	0
Interest Income	438K	894K	996K	0	0	0	0	0	0	0
Interest Expense	806K	347K	971K	0	0	0	0	0	0	0
Other Income/Expense	-473K	-1.06M	947K	-246K	82K	322K	-171K	1.17M	4.81M	10.29M
Pretax Income+	-74.29M	-58.18M	-52.93M	-62.97M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.6M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-300K	-900K	-1.6M	0	0	0	0	0	0
Effective Tax Rate %	1%	0.99%	0.98%	0.97%	1%	1%	1%	1%	1%	1%
Net Income+	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.33M	-50.64M	-35.35M	-36.95M	-80.6M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-1.03%	0.22%	0.1%	-0.18%	0.62%	-0.83%	-0.2%	0.3%	-0.05%	-1.18%
Net Income (Continuing)	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-33.32	-25.44	-22.76	-22.85	-2.51	-3.56	-2.93	-1.33	-0.84	-1.32
EPS Growth %	-1.2%	0.24%	0.11%	-0%	0.89%	-0.42%	0.18%	0.55%	0.37%	-0.57%
EPS (Basic)	-33.32	-25.44	-22.76	-22.85	-2.51	-3.56	-2.93	-1.33	-0.84	-1.32
Diluted Shares Outstanding	2.23M	2.27M	2.29M	2.69M	9.21M	11.88M	17.16M	25.76M	43.9M	61.26M
Basic Shares Outstanding	2.23M	2.27M	2.29M	2.69M	9.21M	11.88M	17.16M	25.76M	43.9M	61.26M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	188.11M	130.9M	104.92M	121.33M	4.75M	97.95M	72.2M	120.74M	90.17M	195.3M
Cash & Short-Term Investments	185.08M	129.19M	102.05M	118.07M	1.01M	92.64M	70.1M	118.43M	86.79M	183.45M
Cash Only	35.59M	32.35M	40.78M	49.33M	1.01M	68.15M	70.1M	26.82M	26.75M	33.22M
Short-Term Investments	149.48M	96.84M	61.27M	68.73M	0	24.49M	0	91.6M	60.04M	150.24M
Accounts Receivable	1.32M	347K	946K	1.54M	158K	32K	208K	0	0	1.05M
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.71M	1.36M	1.93M	1.73M	448K	251K	279K	238K	709K	10.8M
Total Non-Current Assets+	996K	722K	585K	432K	451K	6.73M	6.46M	5.67M	5.76M	4.92M
Property, Plant & Equipment	902K	661K	528K	375K	361K	4.98M	4.46M	3.69M	3.76M	3.72M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	1.34M	0
Other Non-Current Assets	94K	61K	57K	57K	90K	1.76M	2.01M	1.98M	659K	1.2M
Total Assets+	189.11M	131.62M	105.51M	121.76M	5.2M	104.69M	78.67M	126.41M	95.94M	200.22M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.61%	-0.3%	-0.2%	0.15%	-0.96%	19.13%	-0.25%	0.61%	-0.24%	1.09%
Total Current Liabilities+	16.54M	9.89M	7.29M	13.31M	5.89M	8.99M	8.85M	10.71M	9.51M	24.36M
Accounts Payable	0	0	0	909K	3.54M	2.63M	1.66M	1.69M	1.28M	2.42M
Days Payables Outstanding	-	-	-	1.27K	16.56K	6.2K	-	-	-	-
Short-Term Debt	2.94M	3.59M	0	5.46M	0	0	0	0	0	0
Deferred Revenue (Current)	-1000K	-1000K	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	9.05M	6.3M	4.27M	4.65M	0	0	0	0	0	0
Current Ratio	11.37x	13.23x	14.39x	9.12x	0.81x	10.89x	8.16x	11.28x	9.49x	8.02x
Quick Ratio	11.37x	13.23x	14.39x	9.12x	0.81x	10.89x	8.16x	11.28x	9.49x	8.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.45M	0	20M	15.19M	0	6M	5.41M	4.8M	4.71M	4.06M
Long-Term Debt	3.45M	0	20M	15.19M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	6M	5.41M	4.8M	4.71M	4.06M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	20M	9.89M	27.29M	28.49M	5.89M	14.99M	14.25M	15.5M	14.21M	28.41M
Total Debt+	6.39M	3.59M	20M	20.64M	97K	6.52M	6M	5.41M	5.55M	5.12M
Net Debt	-29.21M	-28.76M	-20.78M	-28.69M	-912K	-61.63M	-64.09M	-21.42M	-21.2M	-28.1M
Debt / Equity	0.04x	0.03x	0.26x	0.22x	-	0.07x	0.09x	0.05x	0.07x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-91.58x	-164.62x	-55.48x	-	-	-	-	-	-	-
Total Equity+	169.11M	121.73M	78.22M	93.27M	-694K	89.69M	64.41M	110.9M	81.72M	171.81M
Equity Growth %	0.62%	-0.28%	-0.36%	0.19%	-1.01%	130.24%	-0.28%	0.72%	-0.26%	1.1%
Book Value per Share	75.85	53.51	34.21	34.73	-0.08	7.55	3.75	4.31	1.86	2.80
Total Shareholders' Equity	169.11M	121.73M	78.22M	93.27M	-694K	89.69M	64.41M	110.9M	81.72M	171.81M
Common Stock	27K	27K	27K	37K	6K	15K	18K	43K	43K	64K
Retained Earnings	-179.67M	-237.55M	-289.58M	-350.94M	-23.13M	-65.61M	-116.25M	-151.6M	-188.55M	-269.16M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-207K	-80K	-58K	-33K	0	1K	0	-31K	81K	148K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-59.55M	-51.98M	-43.78M	-51.49M	-22.7M	-42.2M	-42.1M	-27.57M	-33.46M	-70.76M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.11%	0.13%	0.16%	-0.18%	0.56%	-0.86%	0%	0.35%	-0.21%	-1.11%
Net Income	-74.29M	-57.88M	-52.03M	-61.37M	-23.13M	-42.48M	-50.64M	-35.35M	-36.95M	-80.6M
Depreciation & Amortization	70K	212K	188K	261K	78K	155K	326K	318K	311K	318K
Stock-Based Compensation	8.58M	0	0	173K	0	2.16M	5.47M	6.62M	0	8.8M
Deferred Taxes	-8.58M	0	0	-9.63M	0	0	0	0	0	0
Other Non-Cash Items	9.09M	10.64M	9.08M	9.78M	129K	10K	-15K	-820K	5.69M	-5.45M
Working Capital Changes	6.73M	-5.5M	-99K	593K	226K	-2.04M	2.75M	1.67M	-2.51M	6.17M
Change in Receivables	-1.01M	970K	-553K	-666K	1.29M	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	4.91M	4.92M	-448K	432K	2.63M	-3.29M	-974K	26K	-403K	1.14M
Cash from Investing+	-92.12M	51.45M	35.65M	-6.87M	-83K	17.09M	24.17M	-90.96M	33.35M	-85.39M
Capital Expenditures	-595K	-660K	-55K	-108K	-83K	-62K	-333K	-100K	-164K	-515K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-19K	35K	35.7M	-6.76M	0	41.93M	24.5K	-90.86K	0	0
Cash from Financing+	129.16M	-2.71M	16.56M	66.91M	19.39M	93.59M	19.89M	75.26M	30K	161.88M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	18M	0	0	0	77K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-60.15M	-52.63M	-43.84M	-51.59M	-22.78M	-42.26M	-42.44M	-27.67M	-33.62M	-71.28M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.13%	0.12%	0.17%	-0.18%	0.56%	-0.86%	-0%	0.35%	-0.22%	-1.12%
FCF per Share	-26.98	-23.14	-19.18	-19.21	-2.47	-3.56	-2.47	-1.07	-0.77	-1.16
FCF Conversion (FCF/Net Income)	0.80x	0.90x	0.84x	0.84x	0.98x	1.00x	0.83x	0.78x	0.91x	0.88x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-54.31%	-39.8%	-52.04%	-71.57%	-49.97%	-95.12%	-65.72%	-40.33%	-38.36%	-63.58%
Return on Invested Capital (ROIC)	-57.13%	-36.79%	-53.73%	-77.1%	-55.29%	-242.7%	-266.74%	-61.01%	-41.76%	-66.76%
Debt / Equity	0.04x	0.03x	0.26x	0.22x	-	0.07x	0.09x	0.05x	0.07x	0.03x
Interest Coverage	-91.58x	-164.62x	-55.48x	-	-	-	-	-	-	-
FCF Conversion	0.80x	0.90x	0.84x	0.84x	0.98x	1.00x	0.83x	0.78x	0.91x	0.88x

Frequently Asked Questions

Growth & Financials

Larimar Therapeutics, Inc. (LRMR) grew revenue by 0.0% over the past year. Growth has been modest.

Larimar Therapeutics, Inc. (LRMR) reported a net loss of $132.0M for fiscal year 2024.

Dividend & Returns

Larimar Therapeutics, Inc. (LRMR) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.

Larimar Therapeutics, Inc. (LRMR) had negative free cash flow of $96.8M in fiscal year 2024, likely due to heavy capital investments.